Healthcare Industry News: Onset Therapeutics
News Release - September 18, 2007
PhotoMedex Hires Paul TanPiengco as Director of MarketingMONTGOMERYVILLE, Pa.--(HSMN NewsFeed)--PhotoMedex, Inc. (Nasdaq: PHMD ) today announced the appointment of Paul TanPiengco to the position of Director of Marketing. He will report directly to Jeff O'Donnell, President and CEO. Most recently, Mr. TanPiengco was Director of Product Management at Onset Therapeutics, a Rhode Island based wound care and dermatology company, where he was responsible for developing and implementing sales and marketing strategies including the launch of multiple products. Prior to that, he worked at Biogen Idec and for more than ten years at BAYER Corp., where he held positions of increasing responsibility.
Mr. TanPiengco received both his M.S. and B.S. degrees in Biology from the University of Hartford, in Connecticut. He also holds an MBA degree from Rensselaer Polytechnic Institute in Troy, New York.
Mr. TanPiengco commented: "It is exciting to be part of the dynamic growth of PhotoMedex. The XTRAC system represents an important treatment option for psoriasis sufferers, as evidenced by its growth in the marketplace."
PhotoMedex's President and CEO Jeff O'Donnell, commented, "As the XTRAC system continues to gain momentum in the marketplace, it is time to add expertise to our marketing organization. We are delighted to welcome Paul to the PhotoMedex management team and we will draw on Paul's significant and relevant experience in support of our goals. We are excited about the opportunities that PhotoMedex has ahead of it and believe Paul will become a crucial element in maximizing those opportunities."
PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC® laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. In addition, the Company provides contract medical procedures to hospitals, surgi-centers and doctors' offices, offering a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics, and other surgical specialties. The Company is a leader in the development, manufacturing and marketing of medical laser products and services. In addition, as a result of the merger with ProCyte, PhotoMedex now develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena®, a Johnson & Johnson company. ProCyte brands include Neova®, Ti-Silc®, VitalCopper®, Simple Solutions® and AquaSante®.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.